Results of Mirogabalin Treatment for Diabetic Peripheral Neuropathic Pain in Asian Subjects: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Study
Abstract Introduction Almost one-quarter of Asian patients with diabetes experience diabetic peripheral neuropathic pain (DPNP), which may be associated with moderate or severe levels of pain, insomnia, mood disorders, and worsened quality of life. Current treatments are generally ineffective and ma...
Main Authors: | Masayuki Baba, Masanori Kuroha, Shoichi Ohwada, Emiko Murayama, Norimitsu Matsui |
---|---|
Format: | Article |
Language: | English |
Published: |
Adis, Springer Healthcare
2020-02-01
|
Series: | Pain and Therapy |
Subjects: | |
Online Access: | https://doi.org/10.1007/s40122-020-00156-6 |
Similar Items
-
Mirogabalin for the treatment of diabetic peripheral neuropathic pain: A randomized, double‐blind, placebo‐controlled phase III study in Asian patients
by: Masayuki Baba, et al.
Published: (2019-09-01) -
Long‐term safety and efficacy of mirogabalin in Asian patients with diabetic peripheral neuropathic pain
by: Masayuki Baba, et al.
Published: (2020-05-01) -
Short-term outcomes of mirogabalin in patients with peripheral neuropathic pain: a retrospective study
by: Tomoko Tetsunaga, et al.
Published: (2020-05-01) -
Mirogabalin and emerging therapies for diabetic neuropathy
by: Javed S, et al.
Published: (2018-08-01) -
Mirogabalin in Japanese Patients with Renal Impairment and Pain Associated with Diabetic Peripheral Neuropathy or Post-Herpetic Neuralgia: A Phase III, Open-Label, 14-Week Study
by: Baba M, et al.
Published: (2020-07-01)